Genentech as part of the Roche Group is at the forefront when it comes to collaboration with biotechs at all development stages to drive the application of technology and modality platforms that have the potential to transform discovery as well as generate innovative medicines beyond the standard of care.
Skyhawk – research collaboration to discover and develop small molecule RNA splicing modifiers for oncology and neurodegenerative diseases
Heptares – research collaboration to discover and develop novel medicines that modulate G-protein-coupled receptor targets across a range of diseases
Barbara Lueckel, Head of Research Technologies, Pharma Partnering
Mark Schiebler, Search & Evaluation Lead Research Technologies, Pharma Partnering